Monte Rosa Expands Molecular Glue Degrader Therapies with AI-Driven Target Discoveries

Monte Rosa Therapeutics has published a research article in Science detailing the discovery of a broad range of human proteins that can be targeted by cereblon (CRBN)-based degradation. The company's proprietary AI and ML engine analyzed protein surfaces at unprecedented scale, identifying previously unrecognized surfaces capable of recruiting cereblon. This greatly expands the reach of Molecular Glue Degrader (MGD) drugs and broadens Monte Rosa's therapeutic reach in immunology, inflammation, and oncology.